Bayer HealthCare

Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat

Bayer HealthCare today announced positive data from the interim analysis of the on-going PATENT-2 trial with riociguat, the open-label long-term extension of the pivotal Phase III study PATENT-1, at the American Thoracic Society International Conference, Philadelphia, USA. more

In Focus

Healthcare News
Photos & Videos

Healthcare News

2013-05-20 Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat

2013-05-20
Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat

Riociguat showed good long-term safety profile(1) / Riociguat demonstrated significant and sustained improvements in six minute walking distance (6MWD) and WHO functional class (FC) in patients with pulmonary arterial hypertension (PAH)(1) more
2013-05-17 Bayer European Regulatory update on Diane-35

2013-05-17
Bayer European Regulatory update on Diane-35

Bayer HealthCare Pharmaceuticals welcomes the statement of the Product Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) affirming the positive benefit-risk profile of Diane-35 provided that several measures are implemented to minimize the risk of thromboembolism. more
2013-05-17 Bayer Submits Investigational Drug Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension for Regulatory Approval in Japan

2013-05-17
Bayer Submits Investigational Drug Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension for Regulatory Approval in Japan

Bayer HealthCare has filed the oral investigational drug riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) for regulatory approval in Japan. more